CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Chidamide Combined with Decitabine, Venetoclax, and Low-Dose Cytarabine (LDAC) for Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Case Series
Provisionally accepted
- West China Hospital, Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Relapsed/refractory acute myeloid leukemia (R/R AML) carries a poor prognosis. We report three patients with R/R AML, each of whom had relapsed after at least two prior chemotherapy regimens or hematopoietic stem-cell transplantation (HSCT), treated with chidamide, decitabine, venetoclax, and low-dose cytarabine (LDAC) (CHI-DEC-VEN-LDAC). After a single treatment cycle, all three patients achieved complete remission (CR), and two attained minimal residual disease (MRD) negativity. Adverse events were manageable, primarily consisting of cytopenias and infections, with no treatment-related deaths. These results suggest that the therapy is effective and well-tolerated, particularly in patients with R/R AML who have had extensive prior treatment. The regimen shows promise as a potential bridging or debulking strategy, but further research with larger cohorts and longer follow-up is needed to confirm its long-term efficacy. These cases highlight the potential benefits of chemotherapy-free or low-chemotherapy approaches for R/R AML treatment.
Keywords: case series, Chidamide, combination therapy, epigenetic therapy, relapsed/refractory acute myeloid leukemia (R/R AML), Single-center study, venetoclax
Received: 07 Dec 2025; Accepted: 04 Feb 2026.
Copyright: © 2026 Li, Ji and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jie Ji
Yu Wu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.